Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Executive Summary
US FDA extends review timeline for the multiple sclerosis BLA until March 28, 2017 to have time to review new information about commercial manufacturing process, Roche says.
You may also be interested in...
Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.
MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report
List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.
US FDA’s First Complete Response Letter Of 2017 Involves … Manufacturing
Tesaro’s IV formulation of Varubi draws letter keeping with last year’s emerging trend of manufacturing-related CRLs, in this case agency concerns about CMC data related to comparability of drug produced by two different contractors; issue seems unlikely to significantly delay approval of the new version of CINV drug, however.